PMID- 26885881 OWN - NLM STAT- MEDLINE DCOM- 20170609 LR - 20181113 IS - 1945-7197 (Electronic) IS - 0021-972X (Print) IS - 0021-972X (Linking) VI - 101 IP - 4 DP - 2016 Apr TI - Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis. PG - 1719-28 LID - 10.1210/jc.2015-4062 [doi] AB - CONTEXT: Dehydroepiandrosterone (DHEA) and T hormones are advertised as antiaging, antiobesity products. However, the evidence that these hormones have beneficial effects on adipose tissue metabolism is limited. OBJECTIVE: The objective of the study was to determine the effect of DHEA and T supplementation on systemic lipolysis during a mixed-meal tolerance test (MMTT) and an iv glucose tolerance test (IVGTT). DESIGN: This was a 2-year randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted at a general clinical research center. PARTICIPANTS: Sixty elderly women with low DHEA concentrations and 92 elderly men with low DHEA and bioavailable T concentrations participated in the study. INTERVENTIONS: Elderly women received 50 mg DHEA (n = 30) or placebo (n = 30). Elderly men received 75 mg DHEA (n = 30), 5 mg T (n = 30), or placebo (n = 32). MAIN OUTCOME MEASURES: In vivo measures of systemic lipolysis (palmitate rate of appearance) during a MMTT or IVGTT. RESULTS: At baseline there was no difference in insulin suppression of lipolysis measured during MMTT and IVGTT between the treatment groups and placebo. For both sexes, a univariate analysis showed no difference in changes in systemic lipolysis during the MMTT or IVGTT in the DHEA group and T group when compared with placebo. There was no change in the results after adjusting for the resting energy expenditure, except for a small, but significant (P = .03) lowering of MMTT nadir palmitate rate of appearance in women who received DHEA. CONCLUSION: In elderly individuals with concentrations of DHEA (men and women) or T (men) below the normal range for young adults, supplementation of these hormones has no effect on insulin suppression of systemic lipolysis. FAU - Espinosa De Ycaza, Ana E AU - Espinosa De Ycaza AE AD - Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905. FAU - Rizza, Robert A AU - Rizza RA AD - Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905. FAU - Nair, K Sreekumaran AU - Nair KS AD - Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905. FAU - Jensen, Michael D AU - Jensen MD AD - Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905. LA - eng SI - ClinicalTrials.gov/NCT00254371 GR - P01 AG014383/AG/NIA NIH HHS/United States GR - M01 RR000585/RR/NCRR NIH HHS/United States GR - R37 DK040484/DK/NIDDK NIH HHS/United States GR - R01 DK040484/DK/NIDDK NIH HHS/United States GR - T32 DK007352/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20160217 PL - United States TA - J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism JID - 0375362 RN - 3XMK78S47O (Testosterone) RN - 459AG36T1B (Dehydroepiandrosterone) SB - IM MH - Aged MH - Body Composition/drug effects MH - Body Weight/drug effects MH - Dehydroepiandrosterone/*administration & dosage MH - Double-Blind Method MH - Female MH - Hormone Replacement Therapy MH - Humans MH - Lipolysis/*drug effects MH - Male MH - Middle Aged MH - Testosterone/*administration & dosage/blood PMC - PMC5399517 EDAT- 2016/02/18 06:00 MHDA- 2017/06/10 06:00 PMCR- 2017/04/01 CRDT- 2016/02/18 06:00 PHST- 2016/02/18 06:00 [entrez] PHST- 2016/02/18 06:00 [pubmed] PHST- 2017/06/10 06:00 [medline] PHST- 2017/04/01 00:00 [pmc-release] AID - 15-4062 [pii] AID - 10.1210/jc.2015-4062 [doi] PST - ppublish SO - J Clin Endocrinol Metab. 2016 Apr;101(4):1719-28. doi: 10.1210/jc.2015-4062. Epub 2016 Feb 17.